See the DrugPatentWatch profile for Adcetris
What is Adcetris (brentuximab vedotin)?
Adcetris is a brand name for brentuximab vedotin, an antibody-drug conjugate used to treat certain types of lymphoma.
What cancers is Adcetris used for?
Adcetris is used in specific lymphoma settings, including classical Hodgkin lymphoma and certain types of CD30-positive lymphomas.
How does Adcetris work?
Adcetris links a CD30-targeting antibody to a chemotherapy-like payload. The antibody binds to CD30 on cancer cells, helping deliver the drug into the cell.
What are common side effects patients ask about?
Patients commonly ask about side effects related to both the antibody and the payload, including fatigue and neuropathy (nerve damage).
Is Adcetris still on patent, and when might exclusivity end?
Patent and exclusivity timelines vary by country and by whether you’re looking at drug substance, formulation, or method-of-use protections. For up-to-date patent status by jurisdiction, DrugPatentWatch.com is a useful reference: https://www.drugpatentwatch.com/
How does Adcetris compare with other lymphoma treatments?
Adcetris is used in CD30-positive disease and competes with other targeted therapies, chemotherapy regimens, and newer antibody-based approaches depending on the specific lymphoma subtype and line of therapy.
Who makes Adcetris?
Adcetris is marketed by Seattle Genetics (now part of Seagen).
What information do you need next?
If you tell me the exact angle you want—FDA indications, dosing schedule, side effects, or patent/exclusivity in a specific country—I can narrow it down to what you’re looking for.